



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2722244 C 2016/09/13

(11)(21) **2 722 244**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) **Date de dépôt PCT/PCT Filing Date:** 2009/05/14
(87) **Date publication PCT/PCT Publication Date:** 2009/11/19
(45) **Date de délivrance/Issue Date:** 2016/09/13
(85) **Entrée phase nationale/National Entry:** 2010/10/21
(86) **N° demande PCT/PCT Application No.:** JP 2009/059300
(87) **N° publication PCT/PCT Publication No.:** 2009/139504
(30) **Priorité/Priority:** 2008/05/15 (JP2008-128259)

(51) **Cl.Int./Int.Cl. A61K 9/16** (2006.01),
A61K 31/4709 (2006.01)
(72) **Inventeur/Inventor:**
MUKAI, TADASHI, JP
(73) **Propriétaire/Owner:**
OTSUKA PHARMACEUTICAL CO., LTD., JP
(74) **Agent:** KIRBY EADES GALE BAKER

(54) **Titre : FORMULATION PHARMACEUTIQUE SOLIDE**
(54) **Title: A SOLID PHARMACEUTICAL FORMULATION**

(57) **Abrégé/Abstract:**

The present invention relates to a sustained-release solid pharmaceutical formulation comprising (a) an active medical ingredient, (b) a pre-gelatinized starch in an amount of 10 to 90 % by weight based on the whole weight of the formulation and (c) one or more kinds of enteric ingredients.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 November 2009 (19.11.2009)

(10) International Publication Number
WO 2009/139504 A3

- (51) **International Patent Classification:**
A61K 9/16 (2006.01) *A61K 31/4709* (2006.01)
- (21) **International Application Number:**
PCT/JP2009/059300
- (22) **International Filing Date:**
14 May 2009 (14.05.2009)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2008-128259 15 May 2008 (15.05.2008) JP
- (71) **Applicant** (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kan-da Tsukasa-machi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).
- (72) **Inventor; and**
- (75) **Inventor/Applicant** (for US only): **MUKAI, Tadashi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).
- (74) **Agents:** **TANAKA, Mitsuo** et al.; AOYAMA & PARTNERS, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka, 5400001 (JP).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report (Art. 21(3))

(88) **Date of publication of the international search report:**
30 September 2010

(54) **Title:** A SOLID PHARMACEUTICAL FORMULATION

(57) **Abstract:** The present invention relates to a sustained-release solid pharmaceutical formulation comprising (a) an active medical ingredient, (b) a pre-gelatinized starch in an amount of 10 to 90 % by weight based on the whole weight of the formulation and (c) one or more kinds of enteric ingredients.



WO 2009/139504 A3

A SOLID PHARMACEUTICAL FORMULATION

TECHNICAL FIELD


[0001] The present invention relates to a solid
5 pharmaceutical formulation. More particularly, it relates
to a sustained-release solid pharmaceutical formulation
comprising (a) an active medical ingredient, especially
cilostazol, (b) a pre-gelatinized starch in an amount of 10
to 90 % by weight based on the whole weight of the
10 formulation and (c) one or more kinds of enteric
ingredients.

BACKGROUND ART

[0002] A sustained-release solid pharmaceutical
15 formulation is a useful formulation since it can control
the blood concentration of an active ingredient to improve
the administration conditions (e.g. reducing administration
frequency), to improve the duration of an active ingredient
which has a short half-life in vivo, to reduce side-effects
20 of an active ingredient whose concentration difference
between the minimum blood concentration and the side-
effects onset concentration is small, and so on.

[0003] Cilostazol is 6-[4-(1-cyclohexyl-1H-tetrazol-5-
yl)butoxy]-3,4-dihydrocarbostyryl as shown in the following
25 formula (1), which exhibits high inhibitory action for

platelet aggregation as well as inhibitory action for phosphodiesterase, antiulcer activity, hypotensive action, antiphlogistic action, etc. and thereby is widely used as an antithrombotic agent, a drug for improving cerebral
5 circulation, an antiinflammatory agent, an antiulcer drug, an antihypertensive drug, an antiasthmatic drug, a phosphodiesterase inhibitor, etc. The cilostazol tablets which are called Pletaal tablet 50[®] and Pletaal tablet 100[®] (OTSUKA PHARMACEUTICAL CO., LTD.) have already been on sale
10 (JP-63(1988)-20235-B). In addition, cilostazol is also used for improving various ischemic diseases such as ulcer, pain and coldness that are symptoms based on chronic arterial occlusion because cilostazol also exhibits a peripheral vasodilatation effect.



15

[0004] Although the conventional cilostazol tablets are generally used in an oral administration of twice per day for an adult, it has been desirable for elderly patients who are typical patients suffering from the indicated
20 disease to improve the administration frequency, preferably to develop a sustained-release formulation thereof which

enables an oral administration of once per day. In addition, it has been also desirable to develop a formulation thereof which is not so affected by a diet because the cilostazol tablet is apt to be affected by a diet, i.e. when administering after meal, $C_{\max}$ increases 2.3 fold and AUC increases 1.4 fold, compared with fasting administration.

In addition, the vasodilatation action of cilostazol can lead to a useful effect such as increase of blood flow. On the contrary, it may cause headache or palpitation. Some patients exposed to cilostazol sometimes suffer from headache as a side-effect of cilostazol. In order to reduce the onset of headache, it is necessary to lessen the maximum plasma level of cilostazol and additionally to develop a sustained-release formulation of cilostazol which can keep a sufficiently effective plasma level thereof on the repeated administration.

[0005] In general, an oral pharmaceutical formulation has to pass through the stomach which is a strong acid region, and through the intestine which is a neutral to basic region. Therefore, in order to develop a sustained-release formulation of an oral pharmaceutical medicament, it is necessary to consider making a medicament able to reach the lower gastrointestinal tract (lower small intestine and large intestine) through various pH-regions.

Furthermore, in order to enable a once-daily administration or keep an effective plasma level of the medicament lessening $C_{\max}$ for reducing a side-effect, it is necessary to sufficiently release the medicament from a sustained-
5 release formulation even after the formulation reaches the lower gastrointestinal tract.

[0006] An enteric formulation coated with an enteric coat is known as a sustained-release formulation which has a sustained-release technique in the lower gastrointestinal
10 tract. However, the technique requires a film coating operation in order to control the drug release via the coat, thus the process of the preparation is troublesome.

[0007] On the other hand, a matrix formulation which is formulated for sustained-release using a methacrylic
15 enteric polymer is also known, which is thought to have a possibility of controlling a detailed drug release due to the sharp pH-responsiveness of the enteric polymer compound. As an example of such formulation, a matrix formulation which is prepared by compressing a mixture of an enteric
20 polymer compound and a medicament is known (e.g. JP-4(1992)-43049-B, JP-6(1994)-199657-A, US 4,968,508, US-2006/0159753-A). In case of such tablet formulation, however, its surface area is small and its solubility is low. Therefore, a formulation comprising a hardly soluble

medicament whose dissolution rate is late may present some drug release problems.

[0008] In addition, JP-6(1994)-24991-A discloses a formulation which is prepared by wet-kneading a powder mixture comprising methacrylic acid copolymer S with ethanol and then by an extrusion granulation technique. This formulation is a granule which is suitably dispersible in gastrointestinal tract, and hence it is possible to lessen the variation between individuals about drug absorption more than in the case of a tablet formulation. However, there is a manufacturing problem when the amount of enteric polymer compound in the matrix formulation is increased to sufficiently control the drug release.

[0009] Although a variety of methods for controlling the drug release were studied as mentioned above, in most of the methods there was a possibility that the drug release rate is changed in the small intestine because of burst phenomenon or intrainestinal pH variations

[0010] A starch has been generally used as an excipient for pharmaceutical formulation because of its excellent stability and safety. Furthermore, when it is used as an additive for a granule prepared by extrusion granulation technique, it eases the procedure of the granulation step. However, it has a disadvantageous lowering of the robustness of the solid formulation, and the drug-release

property of the administered formulation containing a starch is not so good.

[0011] The present inventors had extensively studied a variety of formulations containing a starch as an excipient to solve the above-mentioned problem and had already found that a solid pharmaceutical formulation which is prepared by pre-gelatinizing a starch after mixing a medicament and the starch or after granulating the mixture has a high physical robustness of formulation, an excellent drug-release property of the administered formulation and an excellent digestibility of the excipient (WO 2005/113009). With regard to some medicaments such as cilostazol, however, it has been still necessary to further control the drug-release rate between the small intestine and the large intestine, which are regions located after amylase treatment, in order to sustain its absorption.

SUMMARY OF THE INVENTION

[0011a] Certain exemplary embodiments provide a solid pharmaceutical formulation comprising (a) cilostazol, (b) a pre-gelatinized starch in an amount of 10 to 90 % by weight based on the whole weight of the formulation, (c) one or more kinds of enteric ingredients and (d) an organic acid.

6a

DISCLOSURE OF INVENTION

[0012] An object of the present invention is to solve the above-mentioned problems involved in the solid pharmaceutical formulation containing an active medical
5 ingredient (especially, cilostazol) and a pre-gelatinized starch as an excipient. Namely, an object of the present invention is to provide a sustained-release solid pharmaceutical formulation which can control the drug-

release property in the lower gastrointestinal tract was insufficient, can decrease administration frequency, can reduce side-effects by lessening $C_{\max}$, and so on.

[0013] The present inventors have extensively studied to reach the above object and then have found that the drug release rate after receiving amylase treatment can be controlled by the technique in which an enteric ingredient is added to a pre-gelatinized starch formulation that is a matrix. And also, the present inventors have found that the formulation profile can be further improved by selecting a certain kind of enteric ingredients, and additionally have found that the pharmacokinetics can be affected by adding an organic acid thereto. Based upon the new findings, the present invention has been completed.

[0014] The present invention relates to the following inventions.

[0015] The present invention provides a solid pharmaceutical formulation comprising (a) an active medical ingredient, (b) a pre-gelatinized starch (α -starch) in an amount of 10 to 90 % by weight based on the whole weight of the formulation and (c) one or more kinds of enteric ingredient(s). The active medical ingredient mentioned herein mainly intends to a hardly soluble medicament such as cilostazol. The preferable solid pharmaceutical

formulation is a sustained-release solid pharmaceutical formulation.

Also, the present invention provides the above-mentioned solid pharmaceutical formulation unless the
5 enteric ingredient(s) in (c) consist of only methacrylic acid copolymer LD.

[0016] In addition, the present invention provides the above-mentioned solid pharmaceutical formulation wherein the one or more kinds of enteric ingredients comprise
10 hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, carboxymethylethylcellulose, methacrylic acid copolymer L, and/or methacrylic acid copolymer S.

Preferably, the one or more kinds of enteric
15 ingredients of the present invention are two or more kinds of enteric ingredients that have different pH ranges at which each enteric ingredient can be dissolved, which may be selected from the group consisting of hydroxypropyl methylcellulose acetate succinate, hydroxypropyl
20 methylcellulose phthalate, carboxymethylethylcellulose, methacrylic acid copolymer L, methacrylic acid copolymer S, and methacrylic acid copolymer LD. More preferably, the one or more kinds of enteric ingredients of the present invention are the following two kinds of enteric
25 ingredients: one can be dissolved at a pH of 5 or more, and

the other one can be dissolved at a pH of 6 or more; or one can be dissolved at a pH of 6 or more, and the other one can be dissolved at a pH of 7 or more.

Further, the above-mentioned enteric ingredient(s) preferably comprise a methacrylic acid copolymer unless the enteric ingredient(s) consist of only methacrylic acid copolymer LD. Preferably, the one or more kinds of enteric ingredients comprise methacrylic acid copolymer L and/or methacrylic acid copolymer S, and more preferably, methacrylic acid copolymer L and methacrylic acid copolymer S. The ratio of methacrylic acid copolymer L and methacrylic acid copolymer S is not limited thereto, but preferably, 30:70 to 70:30, 40:60 to 60:40, or about 50:50.

[0017] Furthermore, the present invention provides the above-mentioned solid pharmaceutical formulation which further comprises an organic acid. The organic acid is contained in 0.5 to 5 % by weight, preferably 1 to 3 % by weight, more preferably about 2 % by weight, based on the whole weight of the formulation. The preferable organic acid is, for example, citric acid. Furthermore, the combination of methacrylic acid copolymer S as an enteric ingredient and citric acid as an organic acid is preferred.

[0018] The present invention provides the above-mentioned solid pharmaceutical formulation wherein the material of the pre-gelatinized starch is one or more

starches selected from corn starch, wheat starch, potato starch, rice starch, cassava starch, and tapioca starch. A preferable material of the pre-gelatinized starch is corn starch.

5 [0019] And, the present invention provides the above-mentioned solid pharmaceutical formulation which is in the form of a particle, a granule or a powder. The granule or the powder herein is preferably prepared by an extrusion granulation technique. In addition, the present invention
10 provides a capsule formulation which comprises either the particle solid pharmaceutical formulation or the granular/powdery solid pharmaceutical formulation, or both; or a tablet formulation which comprises either the particle solid pharmaceutical formulation or the granular/powdery
15 solid pharmaceutical formulation, or both.

[0020] Further, the present invention provides a method for preparing the above-mentioned solid pharmaceutical formulation which comprises the following steps (i) and (ii): (i) mixing an active medical ingredient, a starch and
20 one or more kinds of enteric ingredients to prepare a starting composition, and (ii) subjecting the starting composition to a pre-gelatinization of starch. The starch in step (i) includes one or a mixture consisting of a starch, a partly pre-gelatinized starch and/or a pre-gelatinized starch, provided that the starch in step (i) is
25

not only a pre-gelatinized starch. The present invention also provides the above-mentioned method for preparing the solid pharmaceutical formulation wherein the starch is pre-gelatinized by heating during the process of the preparation. In addition, the present invention provides a method for preparing the above-mentioned solid pharmaceutical formulation wherein the heating is accompanied with humidification. Furthermore, the present invention provides a solid pharmaceutical formulation which is prepared by the above-mentioned method.

[0021] And, the present invention provides a capsule formulation which is filled with a rapidly-release granule or powder containing an active medical ingredient, and the sustained-release granule or powder mentioned above.

[0022] The solid pharmaceutical formulation and the method of the preparation thereof are described in detail below.

Solid pharmaceutical formulation

The solid pharmaceutical formulation of the present invention comprises (a) an active medical ingredient, (b) a pre-gelatinized starch and (c) one or more kinds of enteric ingredients.

[0023] The solid pharmaceutical formulation of the present invention contains usually 10 to 90 % by weight, preferably 20 to 80 % by weight, more preferably 25 to 70 %

by weight, of the pre-gelatinized starch (α -starch) based on the whole weight of the formulation. By adding the pre-gelatinized starch in such amount to the formulation, the solid pharmaceutical formulation of the present invention
5 has the desired characteristics, such as high physical robustness of the formulation, and the desired effective and sustained release of the active ingredient within the digestive tract when administered.

[0024] The starch raw material to be used herein is not
10 limited to, but includes any conventional starches such as corn starch, wheat starch, potato starch, rice starch, cassava starch, tapioca starch, which may be used in a single kind of the starches or in combination of two or more kinds of the starches. The starch raw material to be
15 used herein may be a mixture with a partly pre-gelatinized starch and/or pre-gelatinized starch of the above-mentioned starch. The pre-gelatinization of the starch may be carried out during the preparation process of the solid formulation, preferably, in the form of a pharmaceutical
20 composition obtained by mixing the starch with the active ingredient and other pharmaceutical carriers. The pre-gelatinization of the starch includes a partial pre-gelatinization of the starch.

[0025] Preferred pre-gelatinized starches are a pre-
25 gelatinized corn starch, a pre-gelatinized potato starch,

and a pre-gelatinized wheat starch. Particularly preferred pre-gelatinized starch is a pre-gelatinized corn starch, because corn starch has a uniform particle size of 10 to 30 μm and hence is easily processed into the desired formulations. Also the pre-gelatinized product thereof is easily handled, and further because corn starch has lower moisture-absorption characteristics in comparison with other starches.

[0026] The enteric ingredient herein used may be any kinds of general enteric ingredients, not limited as far as it is not dissolved in the stomach, but dissolved in the intestine. Actually, the enteric ingredient includes, for example, enteric cellulose derivatives such as cellulose acetate phthalate, cellulose acetate trimellitate, cellulose acetate succinate, methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, hydroxymethyl-ethylcellulose phthalate, hydroxypropylmethyl cellulose acetate maleate, hydroxypropylmethyl cellulose trimellitate and carboxymethylethylcellulose; vinyl derivatives such as polyvinyl butylate phthalate, polyvinyl alcohol acetate phthalate; enteric acrylate copolymers such as copolymer of methacrylic acid and ethyl acrylate (e.g. methacrylic acid-ethyl acrylate) and copolymer of methacrylic acid and methyl methacrylate (e.g. methacrylic acid copolymer L,

methacrylic acid copolymer S). The enteric ingredient may be used alone or in combination of two or more kinds of ingredients. Amongst them, preferred examples are hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethyl-ethylcellulose, methacrylic acid copolymer L, methacrylic acid copolymer S, and more preferred ones are hydroxypropyl methylcellulose acetate succinate, methacrylic acid copolymer L, and methacrylic acid copolymer S. When using two or more enteric ingredients, it is preferred that each pH range at which each enteric ingredient can be dissolved is different from each other. In this case, the enteric ingredients include hydroxypropyl methylcellulose acetate succinate, hydroxylpropyl methylcellulose phthalate, carboxymethylethylcellulose, methacrylic acid copolymer L, methacrylic acid copolymer S, and methacrylic acid copolymer LD. Further, it is preferred to combine two kinds of enteric ingredients, one that can be dissolved at a pH of 6 or more (e.g. methacrylic acid copolymer L), and the other one that can be dissolved at a pH of 7 or more (e.g. methacrylic acid copolymer S). It is also preferred to combine two kinds of enteric ingredients, one that can be dissolved at a pH of 5 or more, and the other one that can be dissolved at a pH of 6 or more. More preferably, the enteric ingredient is methacrylic acid copolymer L

and/or methacrylic acid copolymer S, and even more preferably, methacrylic acid copolymer L and methacrylic acid copolymer S. In addition, when using one kind of enteric ingredient, it is preferred to combine an organic acid with the enteric ingredient. In this case, the preferable enteric ingredient is hydroxypropyl methylcellulose acetate succinate, methacrylic acid copolymer L, or methacrylic acid copolymer S, and the preferable organic acid is citric acid. The enteric ingredient(s) may be incorporated in an amount of 1 to 30 % by weight, preferably 5 to 20 % by weight, more preferably 5 to 15 % by weight, based on the whole weight of the formulation.

[0027] The active medical ingredient to be incorporated into the solid pharmaceutical formulation of the present invention may be any kinds of medicaments having any pharmaceutical activities as far as they can be administered orally. They may be water-soluble medicaments or hardly water-soluble medicaments. The medicament herein used includes, for example, a conventional medicament, i.e. various medicaments as incorporated in pharmaceutical preparations such as agents for respiratory organs, agents for digestive organs, cardiovascular agents, agents for central nervous system, agents for peripheral nervous system, antibiotics, chemotherapeutics, antitumor agents,

platelet aggregation inhibitors, anti-allergic agents, vitamins, or nutrients. Preferred medicaments are hardly water-soluble medicaments. Further preferred medicaments are classified into Class II (High Permeability, Low Solubility) in "Waiver of in Vivo Bioavailability and Bioequivalents Studies for Immediate Release Solids Dosage Forms Containing Certain Active Moieties/Active Ingredients Based on Biopharmaceutics Classification System (FDA Guidance)" (in this description, it may occasionally be referred to as "Biopharmaceutics Classification System"). When the hardly water-soluble medicament is formulated into a sustained release preparation, it can release the active medicament gradually and effectively within the digestive organs, and hence can exhibit the desired pharmaceutical activities when administered.

[0028] The active medical ingredient may be used alone or as a combination of two or more kinds of the medicaments.

[0029] The active ingredient used in the solid pharmaceutical formulation includes, for example, teophylline, grepafloxacin, carteolol, procaterol, rebamipide, aripiprazole, cilostazol, Physuline, tolvaptan, acetaminophen, nifedipine, ketoprophen, naproxen, diclofenac, itraconazole, piroxicam, phenytoin, and verapamil. Amongst them, preferred example is cilostazol, ketoprophen, naproxen, diclofenac, itraconazole, piroxicam,

phenytoin, or verapamil, and more preferred one is cilostazol. These active ingredients are particularly useful when they are formulated in a sustained release preparation.

5 [0030] The active ingredient may be incorporated into the solid pharmaceutical formulation in an appropriate amount, which may vary depending on the kind and efficacy of the active ingredient, sexes and ages of the patients to be treated, and so on, but may be contained, for example,
10 in the range of about 0.01 to 70 % by weight, preferably 0.1 to 60 % by weight, more preferably 1 to 60 % by weight, based on the whole weight (in dry weight) of the composition.

[0031] The organic acid used in the solid pharmaceutical
15 formulation of the present invention includes, for example, tartaric acid, malic acid, succinic acid, citric acid, maleic acid, acetic acid, oxalic acid, etc. The organic acid may be used alone or in combination of two or more kinds of the organic acids. Amongst them, citric acid is
20 preferable.

[0032] The solid pharmaceutical formulation may further comprise an appropriate amount of various other additives such as excipients, binders, pH adjustors, disintegrators, absorption promoters, lubricants, colorants, flavors,
25 perfumes, and the like, unless they give any adverse affect.

[0033] These additives are, for example, excipients (e.g. lactose, white sugar, mannitol, sodium chloride, glucose, calcium carbonate, kaolin, crystalline cellulose, silicates); binders (e.g. water, ethanol, simple syrup, aqueous glucose solution, aqueous starch solution, aqueous gelatine solution, carboxymethylcellulose, carboxymethylcellulose sodium, sellac, methyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polyvinyl alcohol, gelatin, dextrin, pullulan); pH adjustors (e.g. citric acid, citric anhydride, sodium citrate, sodium citrate dihydrate, anhydrous disodium hydrogenphosphate, anhydrous sodium dihydrogenphosphate, sodium hydrogenphosphate, sodium dihydrogen phosphate); disintegrators (e.g. carmellose calcium, low substituted hydroxypropylcellulose, carmellose, crosscarmellose sodium, carboxymethyl starch sodium, crosspovidone); plasticizers (e.g. polysorbate 80); absorption promoters (e.g. quaternary ammonium bases, sodium laurylsulfate); lubricants (e.g. purified talc, stearates, polyethylene glycol, colloidal silicates,, sucrose fatty acid esters); colorants (e.g. yellow iron oxide, yellow iron sesquioxide, sesquioxide, β -carotene, titanium oxide, food colors such as food blue No. 1, copper chlorophyll, riboflavin); flavors (e.g. ascorbic acid,

aspartame, sweet hydrangea, sodium chloride, fructose, saccharine, powdered sugar).

[0034] The solid pharmaceutical formulation of the present invention may be formulated in any type of solid
5 formulations such as fine powders, particles, powders, granules, tablets, or the like. The solid pharmaceutical formulation of the present invention may further be formulated in the form of coated products or capsules. Amongst these formulations, preferred ones are granules or
10 powders.

[0035] In order to form in granules, it is preferable to incorporate crystalline cellulose into the solid pharmaceutical formulation. By adding crystalline cellulose thereto, the composition can easily be formed in
15 spherical shapes by conventional technique for regulating spherical shape, and hence it can be easily granulated by extrusion granulation technique. Besides, when the composition is formed into spherical shape, it is easy to package into capsules. It is also advantageous that the
20 spherical composition can be effectively coated. The crystalline cellulose may be incorporated in an amount of 2 to 90 % by weight, preferably 5 to 80 % by weight, more preferably 5 to 70 % by weight, based on the whole weight of the pharmaceutical formulation.

[0036] In addition, the capsule formulation of the present invention can keep the blood concentration of an active ingredient constant by filling a rapidly-release granule or powder and a sustained-release granule or a powder which each contain an active medical ingredient.

[0037]

Method of preparation

The solid pharmaceutical formulation of the present invention can be prepared by subjecting a composition comprising an active medical ingredient, a starch and an enteric ingredient (hereinafter, referred to "starting composition") to a pre-gelatinization. In more detail, the solid pharmaceutical formulation can be prepared by the following steps (i) and (ii):

(i) a step of mixing an active medical ingredient, a starch and an enteric ingredient to prepare a starting composition, and

(ii) a step of subjecting the starting composition to a pre-gelatinization of starch.

[0038] The components of the starting composition prepared in the step (i) are still maintained in the final solid pharmaceutical formulation, except that the starch is pre-gelatinized to be converted into α -starch in the step (ii). Accordingly, in the step (i), the active medical ingredient, the starch to be pre-gelatinized, and other

optional ingredients (various carriers) should be incorporated into the starting composition in the same amounts as the final solid pharmaceutical formulation.

[0039] The starting composition contains preferably
5 water in addition to the above-mentioned components. The water content in the starting composition is not limited to specific range, but is usually 30 to 80 % by weight, preferably 40 to 80 % by weight, more preferably 40 to 70 % by weight, based on the whole weight of the starting
10 composition. By adding water in such range as mentioned above, the starting composition can easily be formed into the desired forms and further can be effectively subjected to the subsequent pre-gelatinization step.

[0040] The starting composition may be any type of solid
15 formulations, such as fine powders, powders, granules, tablets, and so on. The shape of the starting composition can be maintained even after being subjected to the pre-gelatinization in the step (ii) to form the desired solid pharmaceutical formulation containing the pre-gelatinized
20 starch (α -starch). Accordingly, the starting composition is preferably formed in the same formulation as the final product suitable for the desired drug.

[0041] The method for formulation of the starting composition into the desired forms is not limited but it
25 may be prepared by a conventional method. When the solid

pharmaceutical formulation is in the form of the granules,
it is preferable to incorporate crystalline cellulose into
the starting composition (the amount of crystalline
cellulose is defined above) and to granulate the
5 composition by extrusion granulation technique in the step
(i).

[0042] The starting composition thus obtained is
subjected to the next step (ii), wherein the starch is pre-
gelatinized so as to be converted into α -starch. The pre-
10 gelatinization may be carried out by a conventional method
for converting a starch raw material into α -starch. For
example, when the starting composition contains water as
mentioned above, the starting composition is subjected to
heat treatment. The heat treatment may be carried out by
15 any conventional heating treatment, for example, heating
with steam, dry heating with hot air, high frequency
induction heating, heating with microwave, and the like.
The heating temperature may vary according to the heating
means, but is usually in the range of 75 to 100°C,
20 preferably 80 to 100°C. The heating time may appropriately
be determined according to the heating means by a person
skilled in the art.

Besides, when the starting composition does not
contain water, the starting composition is preferably
25 subjected to heating with steam, for example, by spraying

water onto the starting composition and then treating with a steam microwave, by which the starch is converted into α -starch. The heating conditions are the same as mentioned above.

5 [0043] When the starting composition contains crystalline cellulose and is in the form of granules prepared by the extrusion granulation technique, the granules have uniform spherical shape (high degree of spherical shape), and hence are suitably subjected to
10 microwave heating. When the starting composition having spherical shape with non-flat (concavo-convex) surface is subjected to microwave heating, the parts having convex surface are first heated and the moisture is distilled off from the surface, and thereby the pre-gelatinization is
15 done with less efficiency. On the other hand, when the starting composition having spherical shape in high degree is subjected to microwave heating, the starting composition is heated first from inner part and hence the surface keeps the moisture with less evaporation during the heating
20 treatment, and thereby, the pre-gelatinization can effectively be done.

[0044] Thus, the starting composition is subjected to the pre-gelatinization of the starch contained in the composition to give the desired formulation containing pre-
25 gelatinized starch (α -starch). The pharmaceutical

formulation resulting from the pre-gelatinization contains moisture and hence is preferably subjected to drying in order to remove the moisture. The drying is carried out by a conventional method, for example, by keeping in a drying
5 room at a temperature of 50 to 90°C, preferably 60 to 80°C. The drying time may be optionally determined depending on the type of the pharmaceutical formulation and the drying temperature, and so on by a person skilled in the art.

[0045] The solid pharmaceutical formulation of the
10 present invention may be a preparation obtained by the above steps (i) and (ii) and optionally a drying step (i.e. the preparation obtained by the pre-gelatinization); or alternatively it may be a preparation obtained by further
15 subjecting "the solid formulation obtained by the pre-gelatinization" to a processing step by any conventional methods which are usually used for preparing pharmaceutical formulations.

For example, the granules obtained by pre-gelatinization may be subjected to tableting to give a
20 solid pharmaceutical formulation in the form of tablets. Besides, the solid pharmaceutical formulation or the further processed product may be subjected to coating to give a coated product. Further, the solid pharmaceutical formulation or the further processed product may be packed

into capsules to give the desired solid pharmaceutical formulation in the form of capsules.

[0046] The solid pharmaceutical formulation of the present invention can be easily prepared since the enteric
5 ingredient is contained as a matrix, and not as a film-coating material. Therefore, the preparation of a granule formulation and a similar formulation of the present invention can be carried out in a shorter time compared with a conventional film-coated formulation and thus it is
10 possible to reduce the manufacturing cost.

In addition, the solid pharmaceutical formulation of the present invention has a high physical robustness of formulation, an excellent drug-release property of an administered formulation, and an excellent digestibility of
15 the excipient. Especially, the drug-release property between the small intestine and the large intestine is excellent. The solid pharmaceutical formulation of the present invention has a property controlling the drug release rate by the action of a certain kind of enteric
20 ingredient and an organic acid after the formulation is digested and disintegrated with amylase in the small intestine. Thereby, it enables a variety of sustained-release properties such as an oral administration of once per day and a reduction of side-effects.

BRIEF DESCRIPTION OF DRAWING

[0047] Fig. 1 is a graph showing dissolution characteristics of the solid pharmaceutical formulations (in Example 1 and Reference Example 1).

5 Fig. 2 is a graph showing dissolution characteristics of the solid pharmaceutical formulations (in Example 2 and Reference Example 2).

Fig. 3 is a graph showing dissolution characteristics of the solid pharmaceutical formulations (in Example 3 and
10 Reference Example 3).

Fig. 4 is a graph showing dissolution characteristics of the solid pharmaceutical formulations (in Example 4 and Reference Example 4).

Fig. 5 is a graph showing dissolution characteristics
15 of the solid pharmaceutical formulations (in Example 5 and Reference Example 5).

Fig. 6 is a graph showing dissolution characteristics of the solid pharmaceutical formulations (in Example 6 and Reference Example 6).

20 Fig. 7 is a graph showing change of average plasma concentration of cilostazol with time on administering the solid pharmaceutical formulations (in Examples 4 - 6 and Reference Example 7) ($n = 7$, mean $\pm$ standard deviation).

BEST MODE FOR CARRYING OUT THE INVENTION

[0048] The present invention is illustrated in more detail by the following examples and experiments, but should not be construed to be limited thereto.

5 [0049]

Example 1

Corn starch (trademark: "NisshokuTM Corn Starch", manufactured by Nippon Shokuhin Kako K.K.) (90 g), crystalline cellulose (trademark: "CEOLUSTM PH301",
10 manufactured by Asahi Kasei Corporation) (30 g), hydroxypropyl methylcellulose acetate succinate (trademark: "AS-HFTM", manufactured by Shin-Etsu Chemical Co., Ltd) (30 g), and cilostazol (manufactured by Otsuka Pharmaceutical Co., Ltd.) (150 g) were mixed, and the mixture was put into
15 a speed kneader (Model number: NSK-150, manufactured by Okada Seiko K.K.), then thereto 37.5 mL of 4 % aqueous polysorbate 80 solution (containing 1.5 g of polysorbate 80) and purified water (92.5 g) were added with stirring to give a starting composition (Starting Composition
20 Example 1).

The starting composition was subjected to extrusion granulation with an extrusion granulator equipped with a dome die (hole diameter: 0.6 mm, DomeGranTM DG-L1, manufactured by DALTON Co. LTD.) to give wet granules. The
25 wet granules were treated with a spheroidizer

(Marumerizer™ QJ-400, manufactured by DALTON Co. LTD.) to regulate the shape and size of the granules, and thereby obtain the starting composition of wet granules.

The starting composition of wet granules was subjected
5 to heating and humidifying with a steam oven (HEALSIO™,
manufactured by SHARP CORPORATION) at "warm mode" for
20 minutes so that the corn starch could be pre-gelatinized.
The granules thus heated/humidified were dried in an air-
drying oven at 60°C for 6 hours to give a solid
10 pharmaceutical formulation in the form of granules (Example
1).

[0050]

Example 2

Corn starch (trademark: "Nisshoku Corn Starch",
15 manufactured by Nippon Shokuhin Kako K.K.) (90 g),
crystalline cellulose (trademark: "CEOLUS PH301",
manufactured by Asahi Kasei Corporation) (30 g),
hydroxypropyl methylcellulose acetate succinate (trademark:
"AS-HF", manufactured by Shin-Etsu Chemical Co., Ltd) (30 g),
20 and cilostazol (manufactured by Otsuka Pharmaceutical Co.,
Ltd.) (150 g) were mixed, and the mixture was put into a
speed kneader (Model number: NSK-150, manufactured by Okada
Seiko K.K.), then thereto 37.5 mL of 4 % aqueous
polysorbate 80 solution (containing 1.5 g of polysorbate
25 80) and purified water (67.5 g) were added with stirring to

give a starting composition (Starting Composition Example 2).

The starting composition was subjected to extrusion granulation with an extrusion granulator equipped with a dome die (hole diameter: 0.6 mm, DomeGran DG-L1, manufactured by DALTON Co. LTD.) to give wet granules. The wet granules were treated with a spheroidizer (Marumerizer QJ-400, manufactured by DALTON Co. LTD.) to regulate the shape and size of the granules, and thereby obtain the starting composition of wet granules.

The starting composition of wet granules was subjected to heating and humidifying with a steam oven (HEALSIO, manufactured by SHARP CORPORATION) at "warm mode" for 20 minutes so that the corn starch could be pre-gelatinized. The granules thus heated/humidified were dried in an air-drying oven at 60°C for 6 hours to give a solid pharmaceutical formulation in the form of granules (Example 2).

[0051]

20 Example 3

Corn starch (trademark: "Nisshoku Corn Starch", manufactured by Nippon Shokuhin Kako K.K.) (69 g), crystalline cellulose (trademark: "CEOLUS PH301", manufactured by Asahi Kasei Corporation) (51 g), methacrylic acid copolymer L (trademark: "EudragitTM L100",

manufactured by EVONIK) (30 g), and cilostazol (manufactured by Otsuka Pharmaceutical Co., Ltd.) (150 g) were mixed, and the mixture was put into a speed kneader (Model number: NSK-150, manufactured by Okada Seiko K.K.), then thereto
5 purified water (130 g) were added with stirring to give a starting composition (Starting Composition Example 3).

The starting composition was subjected to extrusion granulation with an extrusion granulator equipped with a dome die (hole diameter: 0.6 mm, DomeGran DG-L1,
10 manufactured by DALTON Co. LTD.) to give wet granules. The wet granules were treated with a spheroidizer (Marumerizer QJ-400, manufactured by DALTON Co. LTD.) to regulate the shape and size of the granules, and thereby obtain the starting composition of wet granules.

15 The starting composition of wet granules was subjected to heating and humidifying with a steam oven (HEALSIO, manufactured by SHARP CORPORATION) at "warm mode" for 20 minutes so that the corn starch could be pre-gelatinized. The granules thus heated/humidified were dried in an air-
20 drying oven at 60°C for 6 hours to give a solid pharmaceutical formulation in the form of granules (Example 3).

[0052]

Example 4

Corn starch (trademark: "Nisshoku Corn Starch",
manufactured by Nippon Shokuhin Kako K.K.) (69 g),
5 crystalline cellulose (trademark: "CEOLUS PH301",
manufactured by Asahi Kasei Corporation) (21 g), methacrylic
acid copolymer L (trademark: "Eudragit L100", manufactured
by EVONIK) (15 g), methacrylic acid copolymer S (trademark:
"Eudragit S100", manufactured by EVONIK) (15 g), a pre-
10 gelatinized starch (trademark: "Amycol CTM", manufactured
by NIPPON STARCH CHEMICAL CO., LTD.) (30 g), and cilostazol
(manufactured by Otsuka Pharmaceutical Co., Ltd.) (150 g)
were mixed, and the mixture was put into a speed kneader
(Model number: NSK-150, manufactured by Okada Seiko K.K.),
15 then thereto 75 mL of 4 % aqueous polysorbate 80 solution
(containing 3 g of polysorbate 80) and purified water (20
g) were added with stirring to give a starting composition
(Starting Composition Example 4).

The starting composition was subjected to extrusion
20 granulation with an extrusion granulator equipped with a
dome die (hole diameter: 0.6 mm, DomeGran DG-L1,
manufactured by DALTON Co. LTD.) to give wet granules. The
wet granules were treated with a spheroidizer (Marumerizer
QJ-400, manufactured by DALTON Co. LTD.) to regulate the

shape and size of the granules, and thereby obtain the starting composition of wet granules.

The starting composition of wet granules was subjected to heating and humidifying with a steam oven (HEALSIO, manufactured by SHARP CORPORATION) at "warm mode" for 20 minutes so that the corn starch could be pre-gelatinized. The granules thus heated/humidified were dried in an air-drying oven at 60°C for 6 hours to give a solid pharmaceutical formulation in the form of granules (Example 4).

[0053]

Example 5

Corn starch (trademark: "Nisshoku Corn Starch", manufactured by Nippon Shokuhin Kako K.K.) (69 g), crystalline cellulose (trademark: "CEOLUS PH301", manufactured by Asahi Kasei Corporation) (21 g), methacrylic acid copolymer S (trademark: "Eudragit S100", manufactured by EVONIK) (30 g), a pre-gelatinized starch (trademark: "LYCATABTM PGS", manufactured by ROQUETTE) (30 g), and cilostazol (manufactured by Otsuka Pharmaceutical Co., Ltd.) (150 g) were mixed, and the mixture was put into a speed kneader (Model number: NSK-150, manufactured by Okada Seiko K.K.), then thereto 75 mL of 4 % aqueous polysorbate 80 solution (containing 3 g of polysorbate 80) and purified

water (20 g) were added with stirring to give a starting composition (Starting Composition Example 5).

The starting composition was subjected to extrusion granulation with an extrusion granulator equipped with a dome die (hole diameter: 0.6 mm, DomeGran DG-L1, manufactured by DALTON Co. LTD.) to give wet granules. The wet granules were treated with a spheroidizer (Marumerizer QJ-400, manufactured by DALTON Co. LTD.) to regulate the shape and size of the granules, and thereby obtain the starting composition of wet granules.

The starting composition of wet granules was subjected to heating and humidifying with a steam oven (HEALSIO, manufactured by SHARP CORPORATION) at "warm mode" for 20 minutes so that the corn starch could be pre-gelatinized. The granules thus heated/humidified were dried in an air-drying oven at 60°C for 6 hours to give a solid pharmaceutical formulation in the form of granules (Example 5).

[0054]

Example 6

Corn starch (trademark: "Nisshoku Corn Starch", manufactured by Nippon Shokuhin Kako K.K.) (69 g), crystalline cellulose (trademark: "CEOLUS PH301", manufactured by Asahi Kasei Corporation) (21 g), methacrylic acid copolymer S (trademark: "Eudragit S100", manufactured

by EVONIK)(30 g), a pre-gelatinized starch (trademark:
"LYCATAB PGS", manufactured by ROQUETTE)(30 g), citric acid
(6 g), and cilostazol (manufactured by Otsuka
Pharmaceutical Co., Ltd.)(150 g) were mixed, and the
5 mixture was put into a speed kneader (Model number: NSK-150,
manufactured by Okada Seiko K.K.), then thereto 75 mL of
4 % aqueous polysorbate 80 solution (containing 3 g of
polysorbate 80) and purified water (20 g) were added with
stirring to give a starting composition (Starting
10 Composition Example 6).

The starting composition was subjected to extrusion
granulation with an extrusion granulator equipped with a
dome die (hole diameter: 0.5 mm, DomeGran DG-L1,
manufactured by DALTON Co. LTD.) to give wet granules. The
15 wet granules were treated with a spheroidizer (Marumerizer
QJ-400, manufactured by DALTON Co. LTD.) to regulate the
shape and size of the granules, and thereby obtain the
starting composition of wet granules.

The starting composition of wet granules was subjected
20 to heating and humidifying with a steam oven (HEALSIO,
manufactured by SHARP CORPORATION) at "warm mode" for 20
minutes so that the corn starch could be pre-gelatinized.
The granules thus heated/humidified were dried in an air-
drying oven at 60°C for 6 hours to give a solid

pharmaceutical formulation in the form of granules
(Example 6).

[0055]

Reference Examples 1 to 6

5 Without heating/humidifying treatment, the starting
compositions of wet granules (prepared in the procedure in
Examples 1 to 6) were directly dried in a air-drying oven
at 60°C for 6 hours to give solid pharmaceutical
formulations in the form of granules (Reference Examples 1
10 - 6).

[0056]

Experiment 1

 Using the solid pharmaceutical formulations of
Example 1 and Reference Example 1 which are in the form of
15 granules, the following experiment was carried out. Each
of the formulations was weighed out in an amount equivalent
to 100 mg of cilostazol, which was subjected to the
dissolution test according to the following condition:
Test solution: 900 mL of 4 % aqueous polysorbate 80
20 solution; Paddle method (100 rpm). The UV absorption of
the samples collected in each predetermined time was
measured to determine the dissolution rate of the
medicament. Two hours after starting the test, 0.18 g of
amylase (tradename: "α-Amylase", manufactured by Wako Pure
25 Chemical Industries, Limited) was added to each test

solution, and 4 hours after starting the test, a buffer solution was added thereto to adjust pH of each test solution to 7.0.

The results are shown in Fig. 1. With regard to
5 Reference Example 1, the dissolution thereof began immediately after starting the dissolution test, and the drug release rate was hardly affected with an addition of amylase or upper-change of pH. While, with regard to
10 Example 1, the drug release rate sharply rose 4 hours after the dissolution test started, i.e. at the time when pH was changed; and after 6 hours, the drug release rate of Example 1 exceeded the rate of Reference Example 1.

[0057]

Experiment 2

15 Using the solid pharmaceutical formulations of Example 2 and Reference Example 2 which are in the form of granules, the following experiment was carried out. Each of the formulations was weighed out in an amount equivalent to 100 mg of cilostazol, which was subjected to the
20 dissolution test according to the following condition:
Test solution: 900 mL of 0.3 % aqueous sodium laurylsulfate solution; Paddle method (100 rpm). The UV absorption of the samples collected in each predetermined time was measured to determine the dissolution rate of the
25 medicament. Two hours after starting the test, 0.18 g of

amylase (tradename: " α -Amylase", manufactured by Wako Pure Chemical Industries, Limited) was added to each test solution, and 4 hours after starting the test, a buffer solution was added thereto to adjust pH of each test
5 solution to 7.1.

The results are shown in Fig. 2. 2 hours after starting the test, by the addition of amylase, the medicament of Example 2 was rapidly dissolved, and thereby it was confirmed that the action of the pre-gelatinized
10 starch had been preserved.

[0058]

Experiments 3 - 6

Using Examples 3 - 6 and Reference Examples 3 - 6, the same test as Experiment 2 was carried out (Experiments 3 -
15 6). However, the pH resetting 4 hours after starting the dissolution test was "7.1" for Experiments 3, 4 and 5, and "7.5" for Experiment 6. In all cases, as the result of Experiment 2, the dissolutions of Examples 3 - 6 were more sustained than those of Reference Examples 3 - 6 (Fig. 3 -
20 6).

[0059] In conclusion, according to the results of Experiments 1 - 6, it has been found that the formulations of the present invention have two properties, i.e. releasing a medicament in each formulation containing pre-
25 gelatinized starch due to the action that amylase digests

the starch, and additionally controlling the drug release depending on pH due to the addition of an enteric ingredient.

[0060]

5 Evaluation of Pharmacokinetics

Using the granules containing cilostazol prepared in Examples 4 - 6, each granule which contains 100 mg of cilostazol was administered to 7 healthy adult men after meal, and then the blood collection was carried out with
10 time and the concentration of cilostazol in blood was measured.

And, in the same manner, commercially available PletaalTM tablet (containing 50 mg of cilostazol) (Reference Example 7) was administered to 7 healthy adult men after
15 meal, and then the blood collection was carried out with time and the concentration of cilostazol in blood was measured. The results are shown in Table 1 and Fig.7.

Compared with Reference Example, the time-point of C_{max} in all Examples could be delayed. Amongst these results,
20 the result in Example 6 which contained the organic acid exhibited higher C_{max} and AUC than those of Examples 4 and 5. While, the formulations of Examples 4 and 5 (especially, Example 4) exhibited a lessened C_{max} compared with Reference Example, and additionally exhibited a pharmacokinetic

profile which can preserve the activity of a medicament for a long term.

Methacrylic acid copolymer L is an enteric ingredient which can be dissolved at pH 6 or higher, and methacrylic acid copolymer S is an enteric ingredient which can be dissolved at pH 7 or higher. According to the results of Experiments 3 - 5 wherein the dissolution rates of Examples 3 - 5 are shown respectively, it has been found that the higher the pH range at which the contained enteric ingredient can be dissolved is, the slower the dissolution rate is in order to delay the dissolution.

As shown in Fig. 7, however, when each granule of the present invention containing cilostazol was actually administered to healthy adults, the result was inconsistent with the result of dissolution tests (see, the results of Example 4 and Example 5). Namely, the granule whose pH range at which the enteric ingredient can be dissolved is lower (i.e. Example 4, which has lower pH-range thereof than Example 5) has a profile to make the dissolution gradual and make the efficacy sustainably-maintained.

And, it has been found that the solid pharmaceutical formulation containing a combination of two or more enteric ingredients which have different pH-ranges for dissolution (like Example 4) has a pharmacokinetic profile to lessen the C_{max} and keep the blood level constant to make the

efficacy sustainably-maintained for a long period after the administration, compared with the cases using one kind of enteric ingredient.

On the other hand, in the case of Example 6 which
5 contains an enteric ingredient having a higher pH-range for dissolution and further contains an organic acid, it was thought that the dissolution is delayed more and more even if the pH around the medicament rises since the organic acid delays the actual pH-rising. However, in both the
10 result of the dissolution test in Experiment 6 and the result of the pharmacokinetic test herein, the medicament in Example 6 was sharply dissolved after running up the pH range at which the enteric ingredient can be dissolved, though a little delaying of dissolution was observed. It
15 has been found that the solid pharmaceutical formulation further containing an organic acid (e.g. citric acid) together with an enteric ingredient (like Example 6) has a pharmacokinetic profile to dissolve a sufficient amount of medicament for a short period after pH is changed, while
20 lowering the initial dissolution.

Based on the findings, it has become possible to design a sustained-release formulation to fit any purpose by suitably selecting out the compositions of the present invention, and also it might be possible to design a
25 sustained-release formulation which can keep a constant

blood level of a medicament for a long term by combining the present sustained-release formulation and a normal non-sustained-release formulation.

[Table 1]

Formulation	AUC _t (ng·hr/mL)	C _{max} (ng/mL)	T _{max} (hr)	AUC _∞ (ng·hr/mL)
Reference Example 7 (50 mg)	5555	715	2.4	5973
Example 4 (100 mg)	6679	351	11.1	15114
Example 5 (100 mg)	7282	524	7.1	12029
Example 6 (100 mg)	9810	747	7.4	11305

Note) "hr" indicates hour(s).

AUC_t: Area Under a Curve of correlation between the plasma level and elapse of time (in trapezoidal rule)

AUC_∞: Area Under a Curve of correlation between the plasma level and elapse of time till infinite time

C_{max}: Maximum plasma concentration

T_{max}: Time-to- maximum plasma concentration

CLAIMS

1. A solid pharmaceutical formulation comprising
(a) cilostazol, (b) a pre-gelatinized starch in an amount
5 of 10 to 90 % by weight based on the whole weight of the
formulation, (c) one or more kinds of enteric ingredients
and (d) an organic acid.
2. The solid pharmaceutical formulation of claim 1
10 wherein the organic acid is contained in 0.5 to 5 % by
weight.
3. The solid pharmaceutical formulation of claim 1 or 2
wherein the organic acid is citric acid.
- 15 4. The solid pharmaceutical formulation of any one of
claims 1 to 3 wherein the one or more kinds of enteric
ingredients is selected from the group consisting of
hydroxypropyl methylcellulose acetate succinate,
20 hydroxypropyl methylcellulose phthalate,
carboxymethylethylcellulose, methacrylic acid copolymer L
and methacrylic acid copolymer S.

5. The solid pharmaceutical formulation of claim 3 wherein the enteric ingredients comprise methacrylic acid copolymer S.
- 5 6. The solid pharmaceutical formulation of any one of claims 1 to 5 wherein the pre-gelatinized starch is pre-gelatinized corn starch.
7. The solid pharmaceutical formulation of any one of
10 claims 1 to 6 which is prepared by the following steps (i) and (ii):
- (i) mixing cilostazol, a starch, one or more kinds of enteric ingredients and an organic acid to prepare a starting composition, and
- 15 (ii) subjecting the starting composition to a pre-gelatinization of starch.
8. The solid pharmaceutical formulation of claim 7 wherein the starch in (i) is one or a mixture consisting of
20 an unmodified starch, a partly pre-gelatinized starch and/or a pre-gelatinized starch, provided that the starch in (i) is not only a pre-gelatinized starch.
9. The solid pharmaceutical formulation of any one of
25 claims 1 to 8 which is in the form of a particle.

10. The solid pharmaceutical formulation of any one of claims 1 to 8 which is in the form of a granule or a powder.

11. The solid pharmaceutical formulation of claim 10 which
5 is prepared by an extrusion granulation technique.

12. A capsule formulation which comprises the solid pharmaceutical formulation as defined in any one of claims 9 to 11.

10

13. A tablet formulation which comprises the solid pharmaceutical formulation as defined in any one of claims 9 to 11.

15 14. A method for preparing the solid pharmaceutical formulation of any one of claims 1 to 11, wherein the pre-gelatinized starch is pre-gelatinized by heating during the process of the preparation.

20 15. The method of claim 14 wherein the heating is accompanied with humidification.

16. A solid pharmaceutical formulation which is prepared by the method of claim 14 or 15.

25

17. A capsule formulation which is filled with a rapidly-release granule or powder containing cilostazol, and the granule or powder of any one or more of claims 9 to 11.

1/4

Fig. 1





Fig. 2



2/4

Fig. 3





Fig. 4



3/4

Fig. 5





Fig. 6



4/4

Fig. 7

